The trial is designed to assess the therapy's efficacy when administered subcutaneously in single ascending doses.

Those that know, know: Atopic dermatitis, otherwise known as eczema, is no walk in the park—especially for Black folks. According to the National Eczema Association, African Americans are more likely ...

Women are more prone to the condition than men, and Black and Latinx people tend to have more persistent and severe symptoms ...

Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo ...

Bosakitug is a Potential Best-in-Class Investigational Monoclonal Antibody with Demonstrated Superior Potency, Residence Time ...

Karyn Flett first began using steroid treatment when she was 10 - 40 years on she says it has 'ruined her life' ...

A new analysis suggests artificial intelligence algorithms are able to accurately assess lesion severity in patients with ...

The AAP defines proactive care as an “ evidence-based ” approach based on “intermittent use of anti-inflammatory agents (eg, ...

Investors were surely discovering drug discovery company AbCellera Biologics ( ABCL 6.19%) as the trading week kicked off on ...

Sun Pharma’s phase 2 trials of SCD-044 to treat moderate to severe psoriasis and atopic dermatitis fails to meet primary endpoint: Our Bureau, Mumbai Wednesday, June 4, 2025, 11 ...

Symptoms, lesion locations, and morphology are among the features clinicians may use to distinguish hand eczema from hand psoriasis in patients.

Sun Pharma’s experimental drug SCD-044 did not meet its main goals in Phase 2 trials for psoriasis and atopic dermatitis. The ...